The purpose is to demonstrate the efficacy of low-dose interleukin 2 (Ld-IL2) administration in improving clinical course and oxygenation parameters in patients with SARS-CoV2-related ARDS.
About 25% of hospitalized patients with SARS-CoV2 infection presented life-threatening
respiratory conditions. Of these, 60% met ARDS criteria leading to death in 25% to 63% of the
cases. SARS-CoV2-related ARDS is caused by a massive inflammatory cell infiltration leading
to dysregulated cytokine/chemokine responses with lung immunopathological changes. To date,
there is no treatment available.
Regulatory T cells (Treg) are a subpopulation of CD4+ T cells playing a crucial role in the
control of immune responses, in part by preventing excessive inflammation. Depletion of Treg
cells in models of lung infection or after berylium exposure exacerbated lung inflammation.
In contrast, a beneficial role for Treg during early ARDS and its resolution has been
observed.
Low-dose interleukin 2 (Ld-IL2) is the first therapy driving Treg-specific expansion and
activation. Ld-IL2 was successfully tested in a wide range of preclinical models of
inflammatory diseases, including beryllium-induced lung inflammation. Moreover, Ld-IL2 has
been shown to be safe and free of serious adverse events when administered in patients with
various autoimmune diseases. Importantly, in our previous work, we observed only very low
concentrations of IL-2 in the blood (0.1 pg/mL [0.0-2.0]) as well as in the BAL supernatant
(0.8 pg/mL [0.4-1.3]) collected from patients during the early phase of ARDS, suggesting that
additional IL-2 could be beneficial for Treg expansion/activation.
Our objective is therefore to investigate the therapeutic benefit of Ld-IL2 as a Treg inducer
for controlling SARS-CoV2-related ARDS.
After admission of patients to the intensive care unit at one of the recruiting centers, the
eligibility criteria will be checked by the investigating physician and participation in the
study will be proposed to the patient or parent/family member/trusted person. If the patient
is unable to consent and there is no parent/family member/trusted person, the patient may be
included in the emergency procedure.
After inclusion (J0), the patient will be randomized to one of the 2 treatment arms (low dose
IL-2 or placebo).
The experimental treatment will be daily administered to the patient from D1 to D10.
The patient will be monitored daily until D28 during hospitalization.
Drug: 1: ILT101
Subcutaneous injections, once-daily administration for 10 consecutive days.
Drug: 2: Placebo Comparator
placebo in Subcutaneous route
Inclusion Criteria:
- Male or female, age ≥ 18 years
- Laboratory (RT-PCR) confirmed infection with SARS-CoV2
- Patient is either under invasive or non-invasive mechanical ventilation (including
high flow nasal oxygen therapy).
- Diagnosis of ARDS according to the Berlin definition of ARDS
- Onset of ARDS <96 hours
- Patient with French Social Security System
- A written informed consent by the designated substitute decision maker, if present. In
the event of absence, the patient can be included by investigator's decision alone.
Exclusion Criteria:
- Previous history of ARDS in the last month
- Chronic respiratory diseases requiring long-term oxygen therapy and/or long-term
respiratory assistance
- History of organ allograft.
- Active cancer
- Liver cirrhosis with basal Child and Pugh of C
- Pulmonary fibrosis
- Patient with end-of-life decision
- Patient not expected to survive for 24 hours
- Woman known to be pregnant, lactating or with a positive (urine or serum test) or
indeterminate (serum test) pregnancy test
- Patient already enrolled in another interventional pharmacotherapy protocol on
COVID-19
- Patient with known hypersensitivity to natural or recombinant Interleukin-2 or to any
of the excipients
- Presence of any of the following abnormal laboratory values at screening: absolute
neutrophil count (ANC) less than 1.5x109/L, AST or ALT greater than 5 x ULN, platelets
<50,000 per mm3
- Use of chronic oral corticosteroids > 10 mg prednisone equivalent a day for a
non-COVID-19-related condition
- Current uncontrolled autoimmune disease
- Patients with uncontrolled suspected or known active systemic bacterial or fungal
infections
- Patient with severe, uncontrolled pre-existing (chronic) organ failure (myocardial,
hepatic or renal)
- Vaccination with live attenuated vaccines in the month preceding the inclusion
- Patient with burns to ≥ 15% of their total body surface area
- Patient receiving extra-corporeal membrane oxygenation, high-frequency oscillatory
ventilation or any form of extra-corporeal lung support
- Patient under legal protection (protection of the court, or in curatorship or
guardianship).
Service Anesthésie Réanimation - Groupe Hospitalier Pitié-Salpêtrière
Paris, France
Jean-Michel CONSTANTIN, Principal Investigator
Assistance Publique - Hôpitaux de Paris